Idorsia Pharmaceuticals | Sustainability Performance
Biopharmaceutical company focused on the discovery and development of innovative medicines
2017
Switzerland
501 - 1,000 employees
Pharmaceuticals
$100M - 500M in revenue
Not profitable
Sustainability Ranking & Industry Benchmark
#6453
Overall#156
in Switzerland#136
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
Powered by illuminem
Market cap
Revenue
EBITDA
Operating margin
P/E ratio
Revenue & EBITDA
$220.0MFY2025 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
42.7%FY2025
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
-264.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.2
▼ 0.9%
0.1
▲ 41.3%
0.2
▲ 1.8%
0.5
2029Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Available
Recycling policy
Available
Workplace health & safety policy
Available
30%
Independent Directors
3 out of 10 incl. management
Overall score
88
Environment
99
Social
99
Governance
65
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
